483
The Compounding PHY of Beverly HillsThe Compounding PHY of Beverly Hills – FDA 483, Aug 16, 2019
Record Details
An FDA inspection of The Compounding PHY of Beverly Hills revealed critical deficiencies in their non-sterile drug production. The firm used non-pharmaceutical grade water without quality control, lacked essential laboratory testing for components and finished products, and failed to provide employees with current good manufacturing practices (GMP) training. These findings indicate a severe absence of quality assurance in their compounding operations.
View Company Profile
ID · 492711f5-b8a5-4c69-bd13-def654b0f314
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.